# Valneva SE

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Valneva SE).

## Overview

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. Its business combines marketed travel vaccines with a research pipeline of vaccine candidates, and it operates from France with listings in both Europe and the United States.

## Products & services

• Proprietary travel vaccines
• Prophylactic vaccines for infectious diseases
• Vaccine research and clinical development
• Manufacturing and commercialization of vaccines
• Partnered vaccine programs with pharmaceutical companies

- **Commercial travel vaccines** (55%) — Marketed vaccines sold for travel-related and preventive immunization needs.
- **Pipeline vaccines** (25%) — Clinical-stage vaccine candidates targeting infectious diseases and unmet medical needs.
- **Partnered programs** (10%) — Vaccine development programs supported through collaborations and licensing agreements.
- **Manufacturing services** (10%) — Internal and outsourced manufacturing activities supporting vaccine supply.

- Proprietary travel vaccines
- Prophylactic vaccines for infectious diseases
- Vaccine research and clinical development
- Manufacturing and commercialization of vaccines
- Partnered vaccine programs with pharmaceutical companies

## Customers

Valneva sells to travelers, physicians, clinics, distributors, and public-health procurement channels that need preventive vaccines for infectious diseases. Its commercial vaccines address routine travel and protection needs, while its development programs are built to serve larger public-health and partnering opportunities. The company also works with pharmaceutical collaborators on selected vaccine candidates.

- **Travel vaccine buyers** (primary) — Clinics, physicians, and distributors that buy vaccines used before international travel.
- **Public-health procurement** (secondary) — Government and institutional buyers that may purchase vaccines for disease prevention programs.
- **Pharma partners** (secondary) — Partners that collaborate on or commercialize selected vaccine candidates such as Lyme disease programs.
- **End consumers** (primary) — Individuals receiving travel or preventive vaccines through healthcare providers.

- Travel clinics and physicians buying preventive travel vaccines
- Distributors and healthcare channels supplying vaccination products
- Public-health buyers interested in infectious-disease vaccines
- Pharmaceutical partners in co-development or licensing arrangements
- End users seeking protection against travel-related infections

## Geography

Valneva is headquartered in France and references operations and investor communications from Lyon. Its commercial and development activities are international, reflecting vaccine markets that are regulated country by country and sold across travel and public-health channels. The company also reports listings on Nasdaq and Euronext Paris, underscoring access to both U.S. and European capital markets.

- Headquartered in Lyon, France
- Operates across European and international vaccine markets
- Has a U.S. listing on Nasdaq and a European listing in Paris
- Manufacturing and commercial activities support global vaccine supply
- Regulatory and market access differ by country

## Strategy

Valneva’s strategy is to build a specialty vaccine portfolio around products addressing unmet medical needs while expanding its commercial vaccine base. It uses commercial revenue to support advanced development programs, including partnered and wholly owned candidates, and emphasizes differentiated, first-, best- or only-in-class opportunities. The company also prioritizes resource allocation toward core business areas and key strategic projects.

- **Expand commercial vaccine sales** (short-term) — Commercial revenue helps finance the pipeline and supports operating flexibility.
- **Advance clinical pipeline** (medium-term) — Pipeline candidates create future product opportunities and partnering value.
- **Maintain differentiated vaccine positioning** (long-term) — Specialized products with unmet-need focus can support pricing and market access.

- Grow commercial vaccines to fund pipeline development
- Advance differentiated vaccine candidates in clinical development
- Focus on unmet medical needs and niche vaccine categories
- Use partnerships to expand reach and reduce development burden
- Allocate capital toward core business and strategic programs

## Risks

Valneva faces typical vaccine-industry risks tied to clinical development, regulatory approval, manufacturing execution, and demand variability in travel-related products. Company-specific risks also include dependence on a small number of marketed products and on the success of partnered or late-stage candidates, which can materially affect future growth. Foreign-exchange movements, public-health demand swings, and execution of restructuring or capital actions can also affect results.

- **Clinical development failure** [high] — Pipeline value depends on successful trials and regulatory outcomes.
- **Regulatory and approval risk** [high] — Vaccine commercialization requires approvals and ongoing compliance in each market.
- **Concentration in travel vaccines** [medium] — A small commercial portfolio can be sensitive to demand swings and competition.
- **Manufacturing and supply execution** [high] — Vaccines require stringent quality control and reliable production capacity.
- **Foreign exchange volatility** [medium] — International operations create currency translation and transaction exposure.

- Clinical trial failures or delays can reduce pipeline value
- Regulatory approval risk is high in vaccine development
- Travel vaccine demand can fluctuate with mobility patterns
- Manufacturing quality or supply issues can disrupt sales
- Dependence on a limited number of commercial products

## Accounting

Valneva’s results are shaped by revenue recognition for vaccine sales, collaboration revenue, and the timing of clinical or milestone-related income. As a development-stage vaccine company, estimates around R&D assets, impairments, and fair-value or warrant-related measurements can materially affect reported results. The company also uses Adjusted EBITDA as a supplemental measure, so investors should reconcile it carefully to IFRS results and watch for seasonality in vaccine demand.

- **Revenue recognition** — Affects quarterly comparability and reported growth
- **R&D capitalization and impairment** — Can materially change operating results
- **Fair value of financing instruments** — Can create non-cash volatility
- **Seasonality** — Quarterly revenue and margin comparability

- Revenue recognition for vaccine sales and collaborations
- Timing of milestones and partner-related income
- Impairment and recoverability of development assets
- Fair value accounting for financing instruments
- Seasonality in travel-vaccine demand and comparability

---

*Last updated: 2026-09-28T12:18:35.990534+00:00*